Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists
S1P₁ receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P₁ receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoi...
Gespeichert in:
| Veröffentlicht in: | Bioorganic & medicinal chemistry letters 2011-10, Vol.21 (19), p.6013-6018 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6018 |
|---|---|
| container_issue | 19 |
| container_start_page | 6013 |
| container_title | Bioorganic & medicinal chemistry letters |
| container_volume | 21 |
| creator | Buzard, Daniel Han, Sangdon Thoresen, Lars Moody, Jeanne Lopez, Luis Kawasaki, Andrew Schrader, Thomas Sage, Carleton Gao, Yinghong Edwards, Jeff Barden, Jeremy Thatte, Jayant Fu, Lixia Solomon, Michelle Liu, Ling Al-Shamma, Hussien Gatlin, Joel Le, Minh Xing, Charles Espinola, Sheryll Jones, Robert M |
| description | S1P₁ receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P₁ receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acid S1P₁ receptor agonists. |
| doi_str_mv | 10.1016/j.bmcl.2011.05.110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_889178415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>889178415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-a8f04ee51e16fa4dad5e90b38386cb7379dd79e824c51b43ae14cead8c390483</originalsourceid><addsrcrecordid>eNpFkc2KFDEQgIMo7rj6Ah60L6LCpk11kp70UdZfWFDYFbyF6iS9myGTzCY9i7M3fQHf0Sex2xkVCkJRX1WF-gh5DKwGBu2rVd2vTagbBlAzWQOwO2QBohWUCybvkgXrWkZVJ74ekQelrBgDwYS4T44aULIBzhbk5xtfTLpxeVdhtJW5woxmdNnf4uhTrNJQbdLo4vinXFxwZvQ3rhI0fUtU0Bdyjs2Vi7tA4aQ5mQtoPd6mQDndhZc-2hR8pDAn_XbEmLyp0HhbKizVOXz-9eN7hZcp-jKWh-TegKG4R4f3mFy8e3tx-oGefXr_8fT1GTWNakeKamDCOQkO2gGFRStdx3quuGpNv-TLztpl51QjjIRecHQgjEOrDO-YUPyYPN-P3eR0vXVl1OvpDi4EjC5ti1aqg6USICey2ZMmp1KyG_Qm-zXmnQamZw16pWcNetagmdSThqnpyWH8tl87-6_l790n4NkBwGIwDBmj8eU_J1reNt38z6d7bsCk8TJPzJfzaZOcXHLJO8F_A_vemxk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>889178415</pqid></control><display><type>article</type><title>Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Buzard, Daniel ; Han, Sangdon ; Thoresen, Lars ; Moody, Jeanne ; Lopez, Luis ; Kawasaki, Andrew ; Schrader, Thomas ; Sage, Carleton ; Gao, Yinghong ; Edwards, Jeff ; Barden, Jeremy ; Thatte, Jayant ; Fu, Lixia ; Solomon, Michelle ; Liu, Ling ; Al-Shamma, Hussien ; Gatlin, Joel ; Le, Minh ; Xing, Charles ; Espinola, Sheryll ; Jones, Robert M</creator><creatorcontrib>Buzard, Daniel ; Han, Sangdon ; Thoresen, Lars ; Moody, Jeanne ; Lopez, Luis ; Kawasaki, Andrew ; Schrader, Thomas ; Sage, Carleton ; Gao, Yinghong ; Edwards, Jeff ; Barden, Jeremy ; Thatte, Jayant ; Fu, Lixia ; Solomon, Michelle ; Liu, Ling ; Al-Shamma, Hussien ; Gatlin, Joel ; Le, Minh ; Xing, Charles ; Espinola, Sheryll ; Jones, Robert M</creatorcontrib><description>S1P₁ receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P₁ receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acid S1P₁ receptor agonists.</description><identifier>ISSN: 0960-894X</identifier><identifier>EISSN: 1464-3405</identifier><identifier>DOI: 10.1016/j.bmcl.2011.05.110</identifier><identifier>PMID: 21852130</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>agonists ; Animals ; Autoimmune Diseases - drug therapy ; Biological and medical sciences ; butyrates ; Butyrates - chemical synthesis ; Butyrates - pharmacokinetics ; Butyrates - pharmacology ; Disease Models, Animal ; Dogs ; Dose-Response Relationship, Drug ; Drug Discovery ; Drug Evaluation, Preclinical ; Haplorhini ; High-Throughput Screening Assays ; Humans ; Immunomodulators ; Immunosuppressive Agents - chemical synthesis ; Immunosuppressive Agents - pharmacokinetics ; Immunosuppressive Agents - pharmacology ; Indoles - chemical synthesis ; Indoles - pharmacokinetics ; Indoles - pharmacology ; Lymphocytes - metabolism ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Nerve Tissue Proteins - agonists ; Nerve Tissue Proteins - chemistry ; Oxadiazoles - chemical synthesis ; Oxadiazoles - pharmacokinetics ; Oxadiazoles - pharmacology ; Pharmacology. Drug treatments ; Rats ; Rats, Sprague-Dawley ; receptors ; RNA-Binding Proteins - agonists ; RNA-Binding Proteins - chemistry ; Structure-Activity Relationship ; Substrate Specificity</subject><ispartof>Bioorganic & medicinal chemistry letters, 2011-10, Vol.21 (19), p.6013-6018</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c286t-a8f04ee51e16fa4dad5e90b38386cb7379dd79e824c51b43ae14cead8c390483</citedby><cites>FETCH-LOGICAL-c286t-a8f04ee51e16fa4dad5e90b38386cb7379dd79e824c51b43ae14cead8c390483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24636298$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21852130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buzard, Daniel</creatorcontrib><creatorcontrib>Han, Sangdon</creatorcontrib><creatorcontrib>Thoresen, Lars</creatorcontrib><creatorcontrib>Moody, Jeanne</creatorcontrib><creatorcontrib>Lopez, Luis</creatorcontrib><creatorcontrib>Kawasaki, Andrew</creatorcontrib><creatorcontrib>Schrader, Thomas</creatorcontrib><creatorcontrib>Sage, Carleton</creatorcontrib><creatorcontrib>Gao, Yinghong</creatorcontrib><creatorcontrib>Edwards, Jeff</creatorcontrib><creatorcontrib>Barden, Jeremy</creatorcontrib><creatorcontrib>Thatte, Jayant</creatorcontrib><creatorcontrib>Fu, Lixia</creatorcontrib><creatorcontrib>Solomon, Michelle</creatorcontrib><creatorcontrib>Liu, Ling</creatorcontrib><creatorcontrib>Al-Shamma, Hussien</creatorcontrib><creatorcontrib>Gatlin, Joel</creatorcontrib><creatorcontrib>Le, Minh</creatorcontrib><creatorcontrib>Xing, Charles</creatorcontrib><creatorcontrib>Espinola, Sheryll</creatorcontrib><creatorcontrib>Jones, Robert M</creatorcontrib><title>Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists</title><title>Bioorganic & medicinal chemistry letters</title><addtitle>Bioorg Med Chem Lett</addtitle><description>S1P₁ receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P₁ receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acid S1P₁ receptor agonists.</description><subject>agonists</subject><subject>Animals</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Biological and medical sciences</subject><subject>butyrates</subject><subject>Butyrates - chemical synthesis</subject><subject>Butyrates - pharmacokinetics</subject><subject>Butyrates - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Discovery</subject><subject>Drug Evaluation, Preclinical</subject><subject>Haplorhini</subject><subject>High-Throughput Screening Assays</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - chemical synthesis</subject><subject>Immunosuppressive Agents - pharmacokinetics</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Indoles - chemical synthesis</subject><subject>Indoles - pharmacokinetics</subject><subject>Indoles - pharmacology</subject><subject>Lymphocytes - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nerve Tissue Proteins - agonists</subject><subject>Nerve Tissue Proteins - chemistry</subject><subject>Oxadiazoles - chemical synthesis</subject><subject>Oxadiazoles - pharmacokinetics</subject><subject>Oxadiazoles - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>receptors</subject><subject>RNA-Binding Proteins - agonists</subject><subject>RNA-Binding Proteins - chemistry</subject><subject>Structure-Activity Relationship</subject><subject>Substrate Specificity</subject><issn>0960-894X</issn><issn>1464-3405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc2KFDEQgIMo7rj6Ah60L6LCpk11kp70UdZfWFDYFbyF6iS9myGTzCY9i7M3fQHf0Sex2xkVCkJRX1WF-gh5DKwGBu2rVd2vTagbBlAzWQOwO2QBohWUCybvkgXrWkZVJ74ekQelrBgDwYS4T44aULIBzhbk5xtfTLpxeVdhtJW5woxmdNnf4uhTrNJQbdLo4vinXFxwZvQ3rhI0fUtU0Bdyjs2Vi7tA4aQ5mQtoPd6mQDndhZc-2hR8pDAn_XbEmLyp0HhbKizVOXz-9eN7hZcp-jKWh-TegKG4R4f3mFy8e3tx-oGefXr_8fT1GTWNakeKamDCOQkO2gGFRStdx3quuGpNv-TLztpl51QjjIRecHQgjEOrDO-YUPyYPN-P3eR0vXVl1OvpDi4EjC5ti1aqg6USICey2ZMmp1KyG_Qm-zXmnQamZw16pWcNetagmdSThqnpyWH8tl87-6_l790n4NkBwGIwDBmj8eU_J1reNt38z6d7bsCk8TJPzJfzaZOcXHLJO8F_A_vemxk</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Buzard, Daniel</creator><creator>Han, Sangdon</creator><creator>Thoresen, Lars</creator><creator>Moody, Jeanne</creator><creator>Lopez, Luis</creator><creator>Kawasaki, Andrew</creator><creator>Schrader, Thomas</creator><creator>Sage, Carleton</creator><creator>Gao, Yinghong</creator><creator>Edwards, Jeff</creator><creator>Barden, Jeremy</creator><creator>Thatte, Jayant</creator><creator>Fu, Lixia</creator><creator>Solomon, Michelle</creator><creator>Liu, Ling</creator><creator>Al-Shamma, Hussien</creator><creator>Gatlin, Joel</creator><creator>Le, Minh</creator><creator>Xing, Charles</creator><creator>Espinola, Sheryll</creator><creator>Jones, Robert M</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111001</creationdate><title>Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists</title><author>Buzard, Daniel ; Han, Sangdon ; Thoresen, Lars ; Moody, Jeanne ; Lopez, Luis ; Kawasaki, Andrew ; Schrader, Thomas ; Sage, Carleton ; Gao, Yinghong ; Edwards, Jeff ; Barden, Jeremy ; Thatte, Jayant ; Fu, Lixia ; Solomon, Michelle ; Liu, Ling ; Al-Shamma, Hussien ; Gatlin, Joel ; Le, Minh ; Xing, Charles ; Espinola, Sheryll ; Jones, Robert M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-a8f04ee51e16fa4dad5e90b38386cb7379dd79e824c51b43ae14cead8c390483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>agonists</topic><topic>Animals</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Biological and medical sciences</topic><topic>butyrates</topic><topic>Butyrates - chemical synthesis</topic><topic>Butyrates - pharmacokinetics</topic><topic>Butyrates - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Discovery</topic><topic>Drug Evaluation, Preclinical</topic><topic>Haplorhini</topic><topic>High-Throughput Screening Assays</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - chemical synthesis</topic><topic>Immunosuppressive Agents - pharmacokinetics</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Indoles - chemical synthesis</topic><topic>Indoles - pharmacokinetics</topic><topic>Indoles - pharmacology</topic><topic>Lymphocytes - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nerve Tissue Proteins - agonists</topic><topic>Nerve Tissue Proteins - chemistry</topic><topic>Oxadiazoles - chemical synthesis</topic><topic>Oxadiazoles - pharmacokinetics</topic><topic>Oxadiazoles - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>receptors</topic><topic>RNA-Binding Proteins - agonists</topic><topic>RNA-Binding Proteins - chemistry</topic><topic>Structure-Activity Relationship</topic><topic>Substrate Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buzard, Daniel</creatorcontrib><creatorcontrib>Han, Sangdon</creatorcontrib><creatorcontrib>Thoresen, Lars</creatorcontrib><creatorcontrib>Moody, Jeanne</creatorcontrib><creatorcontrib>Lopez, Luis</creatorcontrib><creatorcontrib>Kawasaki, Andrew</creatorcontrib><creatorcontrib>Schrader, Thomas</creatorcontrib><creatorcontrib>Sage, Carleton</creatorcontrib><creatorcontrib>Gao, Yinghong</creatorcontrib><creatorcontrib>Edwards, Jeff</creatorcontrib><creatorcontrib>Barden, Jeremy</creatorcontrib><creatorcontrib>Thatte, Jayant</creatorcontrib><creatorcontrib>Fu, Lixia</creatorcontrib><creatorcontrib>Solomon, Michelle</creatorcontrib><creatorcontrib>Liu, Ling</creatorcontrib><creatorcontrib>Al-Shamma, Hussien</creatorcontrib><creatorcontrib>Gatlin, Joel</creatorcontrib><creatorcontrib>Le, Minh</creatorcontrib><creatorcontrib>Xing, Charles</creatorcontrib><creatorcontrib>Espinola, Sheryll</creatorcontrib><creatorcontrib>Jones, Robert M</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buzard, Daniel</au><au>Han, Sangdon</au><au>Thoresen, Lars</au><au>Moody, Jeanne</au><au>Lopez, Luis</au><au>Kawasaki, Andrew</au><au>Schrader, Thomas</au><au>Sage, Carleton</au><au>Gao, Yinghong</au><au>Edwards, Jeff</au><au>Barden, Jeremy</au><au>Thatte, Jayant</au><au>Fu, Lixia</au><au>Solomon, Michelle</au><au>Liu, Ling</au><au>Al-Shamma, Hussien</au><au>Gatlin, Joel</au><au>Le, Minh</au><au>Xing, Charles</au><au>Espinola, Sheryll</au><au>Jones, Robert M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists</atitle><jtitle>Bioorganic & medicinal chemistry letters</jtitle><addtitle>Bioorg Med Chem Lett</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>21</volume><issue>19</issue><spage>6013</spage><epage>6018</epage><pages>6013-6018</pages><issn>0960-894X</issn><eissn>1464-3405</eissn><abstract>S1P₁ receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P₁ receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acid S1P₁ receptor agonists.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>21852130</pmid><doi>10.1016/j.bmcl.2011.05.110</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-894X |
| ispartof | Bioorganic & medicinal chemistry letters, 2011-10, Vol.21 (19), p.6013-6018 |
| issn | 0960-894X 1464-3405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_889178415 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | agonists Animals Autoimmune Diseases - drug therapy Biological and medical sciences butyrates Butyrates - chemical synthesis Butyrates - pharmacokinetics Butyrates - pharmacology Disease Models, Animal Dogs Dose-Response Relationship, Drug Drug Discovery Drug Evaluation, Preclinical Haplorhini High-Throughput Screening Assays Humans Immunomodulators Immunosuppressive Agents - chemical synthesis Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - pharmacology Indoles - chemical synthesis Indoles - pharmacokinetics Indoles - pharmacology Lymphocytes - metabolism Male Medical sciences Mice Mice, Inbred BALB C Nerve Tissue Proteins - agonists Nerve Tissue Proteins - chemistry Oxadiazoles - chemical synthesis Oxadiazoles - pharmacokinetics Oxadiazoles - pharmacology Pharmacology. Drug treatments Rats Rats, Sprague-Dawley receptors RNA-Binding Proteins - agonists RNA-Binding Proteins - chemistry Structure-Activity Relationship Substrate Specificity |
| title | Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T15%3A41%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20and%20characterization%20of%20potent%20and%20selective%204-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic%20acids%20as%20S1P%E2%82%81%20agonists&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry%20letters&rft.au=Buzard,%20Daniel&rft.date=2011-10-01&rft.volume=21&rft.issue=19&rft.spage=6013&rft.epage=6018&rft.pages=6013-6018&rft.issn=0960-894X&rft.eissn=1464-3405&rft_id=info:doi/10.1016/j.bmcl.2011.05.110&rft_dat=%3Cproquest_cross%3E889178415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=889178415&rft_id=info:pmid/21852130&rfr_iscdi=true |